{
  "id": "5c961281ecadf2e73f000021",
  "type": "list",
  "question": "List 3 indications for rituximab.",
  "ideal_answer": "Rituximab  is used to treat rheumatoid arthritis as well as poly- and dermatomyositis, chronic lymphocytic leukemia, juvenile idiopathic arthritis, and Pemphigus foliaceus (PF).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27603326",
    "http://www.ncbi.nlm.nih.gov/pubmed/28633733",
    "http://www.ncbi.nlm.nih.gov/pubmed/23735074",
    "http://www.ncbi.nlm.nih.gov/pubmed/28185174",
    "http://www.ncbi.nlm.nih.gov/pubmed/23700188",
    "http://www.ncbi.nlm.nih.gov/pubmed/29606668",
    "http://www.ncbi.nlm.nih.gov/pubmed/28536935",
    "http://www.ncbi.nlm.nih.gov/pubmed/30358861"
  ],
  "snippets": [
    {
      "text": "o assess clinical outcomes including imaging findings on computed tomography (CT), pulmonary function testing (PFT), and glucocorticoid (GC) use in patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) treated with rituximab (RTX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606668",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " RIX is the preferred off-label biologic drug for poly- and dermatomyositis in Germany.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536935",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rituximab (RTX) may be a treatment option for children and young people with JIA, although it is not licensed for this indication",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30358861",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " rituximab in children and young people with juvenile idiopathic arthritis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30358861",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "chronic lymphocytic leukemia (CLL) patients, including the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, phosphatidylinositol-3-kinase (PI3K) delta isoform inhibitor idelalisib combined with rituximab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185174",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rituximab's efficacy has been well-documented in adults with refractory PF",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633733",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rituximab in the management of juvenile pemphigus foliaceus",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633733",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND\nRituximab is a chimeric, anti-CD20 monoclonal antibody registered for the treatment of B-cell malignancies and refractory rheumatoid arthritis in Australia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735074",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27603326",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">In our study, off-label rituximab was mainly used for the treatment of hematological, kidney, and systemic connective tissue disorders, and the response among our patient cohort was variable depending on the specific disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23700188",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Rheumatoid arthritis, Chronic Lymphocytic  Leukemia, poly- and dermatomyositis, juvenile idiopathic arthritis, Pemphigus foliaceus"
}